Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Myoma Screw in Manipulation of Large Uterus in Total Laparoscopic Hysterectomy

NCT06976905 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-05
Last updated
2025-05-16

Condition(s) studied

Total Laparoscopic Hysterectomy With Myoma Screw

Investigational drug(s) / intervention(s)

Total laparoscopic hysterectomy

Total laparoscopic hysterectomy: Hysterectomy by laparoscope using uterine manipulator or myoma screw as a manipulator of large uterus

Study summary

To compare between myoma screw and uterine manipulator in manipulation of large uterus in total laparoscopic hysterectomy

Eligibility

Sex
FEMALE
Min age
30 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age 30-60 2. BMI 25-40 3. Large uterus with fundal level 12-24w diagnosed by TAS( Transabdominal Ultrasound)/TVUS(Transvaginal ultrasound) 4. Adenomyosis Exclusion Criteria: 1. BMI more than 40 2. patients with contraindication for laparscopic surgery e.g cardiac and cirrhotic patients

Primary outcome measure(s)

  • Comparison between Magneshkar uterine manipulator and myoma screw in operation time in hours — During surgery in hours
    Using myoma screw as a manipulator in total laparoscopic hysterectomy

Trial sites (1)

FacilityCityRegionStatus
Kafrelsheikh University Kafr ash Shaykh Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06976905 on ClinicalTrials.gov ↗ ← All trials in Egypt